Wednesday, October 01, 2014 7:04:08 PM
4:25pm EDT
Oct 1 (Reuters) - Esperion Therapeutics :
* Esperion Therapeutics Announces Positive Top Line phase 2b results for ETC-1002
* Says ETC-1002-008 study meets primary endpoint; ETC-1002 appears to be safe and well tolerated
* Says ETC-1002 lowers LDL cholesterol significantly more than merck's zetia-study Source text for Eikon: Further company coverage:
Win a few. Lose a few.
Only the long term counts.
Recent ESPR News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/18/2024 07:19:53 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/18/2024 07:09:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/28/2024 08:16:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 08:18:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 08:14:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 08:13:07 PM
- Esperion to Participate in Upcoming June Investor Conferences • GlobeNewswire Inc. • 05/23/2024 01:00:00 PM
- First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk • GlobeNewswire Inc. • 05/22/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2024 08:14:43 PM
- Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia • GlobeNewswire Inc. • 05/20/2024 10:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/17/2024 07:08:17 PM
- Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET® • GlobeNewswire Inc. • 05/14/2024 12:00:00 PM
- Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/10/2024 08:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:31:21 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 12:50:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 11:29:53 AM
- Esperion Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/07/2024 10:00:00 AM
- Esperion to Participate in Upcoming May Investor Conferences • GlobeNewswire Inc. • 04/29/2024 12:00:00 PM
- Esperion to Report First Quarter 2024 Financial Results on May 7 • GlobeNewswire Inc. • 04/23/2024 12:00:00 PM
- Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity • GlobeNewswire Inc. • 04/07/2024 06:45:00 PM
- Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024 • GlobeNewswire Inc. • 04/01/2024 12:00:00 PM
- Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/26/2024 12:00:00 PM
- Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24 • GlobeNewswire Inc. • 03/25/2024 08:00:00 PM
- U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use • Business Wire • 03/22/2024 10:26:00 PM
- U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use • GlobeNewswire Inc. • 03/22/2024 07:10:20 PM
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM